title: [Protective effect of low-dose ketamine against intestinal ischemia-reperfusion injury following carbon dioxide pneumoperitoneum in rats].
abstract: OBJECTIVE
  To investigate the protective effect of low-dose ketamine against intestinal ischemia reperfusion injury following pneumoperitoneum with carbon dioxide in rats.
  
  
  METHODS
  Thirty healthy male adult SD rats (body weight 280-320 g) were randomized into sham-operated group, model group and ketamine group and subjected to pneumoperitoneum for 120 min with carbon dioxide (not in sham-operated group). The rats in ketamine group received an intraperitoneal injection of 10 mg/kg ketamine 10 min before pneumoperitoneum, and those in the other two groups received saline injection. Fifteen minutes after pneumoperitoneum or sham operation, the small intestines were sampled to detect the content of malondialdehyde (MDA) and fore pathological testing. ELISA was used to detect the serum levels of I-FABP, TNF-α IL-6 and IL-8.
  
  
  RESULTS
  Pneumoperitoneum caused a significant increase in intestinal MDA content (P<0.05), which was lowered by ketamine pretreatment (P<0.05). Serum I-FABP, TNF-α, IL-6 and IL-8 levels all significantly increased following pneumoperitoneum (P<0.05) and were obviously lowered by ketamine pretreatment (P<0.05). Pneumoperitoneum also caused obvious pathologies in intestinal mucosa, which were ameliorated by ketamine pretreatment.
  
  
  CONCLUSIONS
  Low-dose ketamine preconditioning can reduce the inflammatory reaction and lessen oxidative damage in the intestinal mucosa following pneumoperitoneum in rats.
authors.affiliation: Department of Anesthesiology, First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an 710061, China.E-mail: xinyuan@stu.xjtu.edu.cn.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Fuhong
authors.initials: F
authors.lastname: Tian
authors.forename: Liushi
authors.initials: L
authors.lastname: Yan
mesh_terms: D000818:Animals; D002245:Carbon Dioxide; D004305:Dose-Response Relationship, Drug; D050556:Fatty Acid-Binding Proteins / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007421:Intestine, Small / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D007649:Ketamine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011027:Pneumoperitoneum / Q000139:chemically induced / Q000150:complications*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000097:blood / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D050556:Fatty Acid-Binding Proteins; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D002245:Carbon Dioxide; D008315:Malondialdehyde; D007649:Ketamine